DNA Cytometry and Nuclear Morphometry in Ovarian Benign, Borderline and Malignant Tumors
DOI:
https://doi.org/10.3889/oamjms.2015.104Keywords:
Ovarian, serous, mucinous, borderline, DNA ploidy, nuclear areaAbstract
BACKDROUND: Ovarian carcinoma is a leading cause of death in gynecological malignancy. Ovarian surface epithelial serous and mucinous tumours are classified as benign, borderline, and malignant. The identification of borderline tumours most likely to act aggressively remains an important clinical issue.
AIM: This work aimed to study DNA ploidy and nuclear area in ovarian serous and mucinous; benign, borderline and malignant tumours.
MATERIAL AND METHODS: This study included forty ovarian (23 serous and 17 mucinous) tumours. Paraffin blocks were sectioned; stained with haematoxylin and eosin for histopathologic and morphometric studies and with blue feulgen for DNA analysis.
RESULTS: All four serous and six out of nine mucinous benign tumours were diploid. All eight serous and five mucinous malignant tumours were aneuploid. Nine of eleven (81.8%) serous and all three mucinous borderline tumours were aneuploid. There were highly significant differences in mean aneuploid cells percentage between serous benign (1.5%), borderline (45.6%) and malignant (74.5%) (p = 0.0001) and between mucinous benign (13.2%) and both borderline (63.7%) and malignant (68.4%) groups (p = 0.0001).There were significant differences in nuclear area between serous benign (26.191%), borderline (45.619%) and malignant (67.634 %) and a significant positive correlation between mean percentage aneuploid value and mean nuclear area in all serous and mucinous groups.
CONCLUSION: We suggest that DNA ploidy and nuclear area combined, may be adjuncts to histopathology; in ovarian serous and mucinous benign, borderline and malignant neoplasms; identifying the aggressive borderline tumours.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Tavassoli F, Devilee P. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon; IARC Press, 2003:114-129.
Dawar R. Surface epithelial tumours of the ovary. Indian Journal of Medical and Paediatric Oncology. 2004;25(1): 5-9. DOI: https://doi.org/10.1055/s-0041-1733055
Holschneider C, Berek J. Ovarian cancer: epidemiology, biology, and prognostic factors. Seminars in Surgical Oncology. 2000; 19: 3-10. http://dx.doi.org/10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S DOI: https://doi.org/10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S
Ono K, Tanaka T, Tsunoda T. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Research. 2000; 60: 5007-11. PMid:11016619
Mokhtar N, Gouda I, Adel I. Malignant female genital system tumors. In Cancer Pathology Registry and Time Trend Analysis 2003-2004. NCI, 2007:77-79.
Bell D. Origins and molecular pathology of ovarian cancer. Modern Pathology. 2005; 18: 19-32. http://dx.doi.org/10.1038/modpathol.3800306 PMid:15761464 DOI: https://doi.org/10.1038/modpathol.3800306
Nucci M, Oliva E. Gynecologic Pathology. UK; Elsevier Chirchill Livingstone, 2009:393-424.
Lee L. Ovarian tumors: an overview. Atlas of Genetics and Cytogenetics in Oncology and Haematology. 2003; 17: 47-52
Lukyanova N, Kulik G, Yurcenko O, et al. Expression of p53 Bcl-2 proteins in epithelial varian carcinoma with different grade of differentiation. Experimental Oncology. 2000; 22(3): 91-93.
Lodhi S, Najam S, Pervez Sh. DNA ploidy analysis of borderline epithelial ovarian tumours. Journal of Pakistan Medical Association. 2000; 50(10): 349-351. PMid:11109755
Barnhill DA, Kurma RJ, Brady MF, et al. Preliminary analysis of the behaviour of stage I ovarian tumours of low malignant potential: A gynecologic oncology group study. J Clin Oncol. 1995;13: 2752-2756. PMid:7595734 DOI: https://doi.org/10.1200/JCO.1995.13.11.2752
Drescher CW, Nelson J, Peacock S, et al. Prognostic significance of DNAcontent and nuclear morphometry in borderline ovarian tumours. Gynecol Oncol. 1993;48: 242-246. http://dx.doi.org/10.1006/gyno.1993.1041 PMid:8428698 DOI: https://doi.org/10.1006/gyno.1993.1041
Böcking A, Chatelain R. Diagnostic and prognostic value of DNA cytometry in gynecologic cytology. Anal Quant Cytol Histol. 1989;11(3):177-86. PMid:2663008
Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J. Diagnosis and treatment of borderline ovarian neoplasms "the state of the art". Eur J Gynaecol Oncol. 2009; 30(5):471-82. PMid:19899396
Korabiowska M, Brinck U, Skubis J, Sattler B, Fischer G. Application of new ploidy-related parameters for the diagnosis of ovarian tumours. Anticancer Res. 2004; 24(6):4191-4. PMid:15736472
Miller BE, Lavia LA, Horbelt DV. The prognostic value of image analysis in ovarian cancer. Cancer. 1991; 67(5):1318-21. http://dx.doi.org/10.1002/1097-0142(19910301)67:5<1318::AID-CNCR2820670508>3.0.CO;2-3 DOI: https://doi.org/10.1002/1097-0142(19910301)67:5<1318::AID-CNCR2820670508>3.0.CO;2-3
El-Deftar MF, El Gerzawi SM, Abdel Azim AA, Tohamy SM. Prognostic significance of ploidy and S-phase fraction in primary intraoral squamous cell carcinomas and their corresponding metastatic lymph nodes. Journal of the National Cancer Institute. 2012;24: 7-14. http://dx.doi.org/10.1016/j.jnci.2011.12.001 DOI: https://doi.org/10.1016/j.jnci.2011.12.001
Demirel D, Laucirica R, Fishman A, Owens RG, Grey MM, Kaplan AL, Ramzy I. Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome. Cancer. 1996; 77(8):1494-500. http://dx.doi.org/10.1002/(SICI)1097-0142(19960415)77:8<1494::AID-CNCR11>3.0.CO;2-V DOI: https://doi.org/10.1002/(SICI)1097-0142(19960415)77:8<1494::AID-CNCR11>3.0.CO;2-V
Veerman MM, van der Wurff AA, van de Water M, Kruitwagen RF, Feijen HW, Vos MC. Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study. Int J Gynecol Pathol. 2009; 28(5):432-41. http://dx.doi.org/10.1097/PGP.0b013e31819b2864 PMid:19696612 DOI: https://doi.org/10.1097/PGP.0b013e31819b2864
Danque PD, Chen HB, Patil J, Jagirdar J, Orsatti G, Paronetto F. Image analysis versus flow cytometry for DNA ploidy quantitation of solid tumors: A comparison of six methods of sample preparation. Mod Pathol. 1993;6: 270 - 275. PMid:8346174
Seidman J, Russell P, Kurman R. Surface epithelial tumors of the ovary. In Kurman,R.(ed), Blaustein's pathology of the female genital tract, 5th ed. USA; Springer-Verlag, New York, 2002:791-905.
Werness B, Eltabbakh G. Familial ovarian cancer and early ovarian cancer: biologic, pathologic, and clinical features. International Journal of Gynecological Pathology. 2001; 20(1): 48-63. http://dx.doi.org/10.1097/00004347-200101000-00005 PMid:11192072 DOI: https://doi.org/10.1097/00004347-200101000-00005
Griffiths AJF, Miller JH, Suzuki DT. An Introduction to Genetic Analysis. 7ed., 2000: Chapter 18.
Aghmesheh M, Saxena A, Niknam F. BrCA1 mutation site may be linked with nuclear DNA ploidy in BRCA-1 mutated ovarian carcinomas. Asia Pac J Clin Oncol. 2015;11 (2): 135-141. http://dx.doi.org/10.1111/ajco.12310 PMid:25428229 DOI: https://doi.org/10.1111/ajco.12310
Blumenfeld Z. Gynecologic concerns for young women exposed to gonadotoxic chemotherapy. Curr Opin Obstet Gynecol. 2003;15: 359-370. http://dx.doi.org/10.1097/00001703-200310000-00003 PMid:14501238 DOI: https://doi.org/10.1097/00001703-200310000-00003
Friedlander ML, Hedley DW, Swanson C, Russel P. Prediction of long term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Onco. 1988;6(2): 282-290. PMid:3276825 DOI: https://doi.org/10.1200/JCO.1988.6.2.282
Barnabei VM, Miller DS, Bauer KD, Murad TM, Radenka AW, Luran R. Flow cytometric evaluaton of epithelial ovarian cancer. Am J Obstet Gynecol. 1990;162: 1584-1592. http://dx.doi.org/10.1016/0002-9378(90)90924-V DOI: https://doi.org/10.1016/0002-9378(90)90924-V
Phisterer J, Kommos T, Sauerbrei W, Renz H, DuBoi A, Keichle-Schwarz M, Pfleiderer A. Cellular DNA content and survival in advanced ovarian carcinoma. Cancer. 1994; 74(9): 2509-2515. http://dx.doi.org/10.1002/1097-0142(19941101)74:9<2509::AID-CNCR2820740919>3.0.CO;2-F DOI: https://doi.org/10.1002/1097-0142(19941101)74:9<2509::AID-CNCR2820740919>3.0.CO;2-F
Griffiths AP, Cross D, Kingston RE, Harkin P, Wells M, Quirke P. Flow cytometry and Ag NORs in benign, borderline and malignant mucinous and serous tumours of the ovary. Int J Gynecol Pathol. 1993;12(4): 307-314. http://dx.doi.org/10.1097/00004347-199310000-00005 PMid:8253547 DOI: https://doi.org/10.1097/00004347-199310000-00005
Kallioniemi OP, Mattila J, Punnonen R, Koivula T. DNA ploidy level and cell cycle distribution in ovarian cancer: relation to histopathological features of the tumor. Int J Gynecol Pathol. 1988; 7(1):1-11. http://dx.doi.org/10.1097/00004347-198803000-00001 PMid:2832334 DOI: https://doi.org/10.1097/00004347-198803000-00001
Castedo M, Senovilla L, Vitale I, Kroemer G. Tetraploid cancer cell precursors in ovarian carcinoma. Cell Cycle. 2012;11(17): 3157-3158. http://dx.doi.org/10.4161/cc.21722 PMid:22895170 PMCid:PMC3466513 DOI: https://doi.org/10.4161/cc.21722
Pradhan M, Davidson B, Tropé CG, Danielsen HE, Abeler VM, Risberg B. Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications. Virchows Arch. 2009;454(6):677-83. http://dx.doi.org/10.1007/s00428-009-0778-y PMid:19421773 DOI: https://doi.org/10.1007/s00428-009-0778-y
Kimmig R, Wimberger P, Hillemanns P, Kapsner T, Caspari C, Hepp H. Multivariate analysis of the prognostic significance of DNA-ploidy and S-pase fraction in ovarian cancer determined by flow cytometry following detection of cytokerarin labelled tumour cells. Gynecol Oncol. 2002;84: 21-31. http://dx.doi.org/10.1006/gyno.2001.6440 PMid:11748971 DOI: https://doi.org/10.1006/gyno.2001.6440
Esposito MJ, Fuchs A. Computerized image analysis and flow cytometric evaluation of ovarian borderline tumors: a study of 24 cases. Cytometry. 1994; 18(4):218-22. http://dx.doi.org/10.1002/cyto.990180405 PMid:7895528 DOI: https://doi.org/10.1002/cyto.990180405
Gamal el Din AA, Esmail RSE, Hareedy AA. Vascular Endothelial Growth Factor in Colonic Cancer, Ulcerative Colitis and Colonic Adenoma: An Immunohistochemical Study. OA Maced J Med Sci. 2014; 2(3):439-443. http://dx.doi.org/10.3889/oamjms.2014.075 DOI: https://doi.org/10.3889/oamjms.2014.075
Cohen C. Image cytometric analysis in pathology. Hum Pathol. 1996; 27(5): 482-93. http://dx.doi.org/10.1016/S0046-8177(96)90091-X DOI: https://doi.org/10.1016/S0046-8177(96)90091-X
Stemberger-Papic S, Stankovic T, Vrdoljak Mozetic D, Versa Ostojik D, Krasevic M, Stifter S, Audi Jurkovic S. Morphometry and digital Ag NOR analysis in cytological imprints of benign, borderline and malignant serous ovarian tumours. Cytopathology. 2006; 17(6): 382-389. http://dx.doi.org/10.1111/j.1365-2303.2006.00330.x PMid:17168922 DOI: https://doi.org/10.1111/j.1365-2303.2006.00330.x
Versa Ostojik D, Stanovic T, Stenberger-Papic S, Vrdoljak Mozetic T, Manestar M, Krasevic M. Nuclear morphometry and AgNOR quantification: Computorized image analysis on ovarian mucinous tumour imprints. Anal Quant Cytol Histol. 2008; 30(3): 160-168.
Zeimet AG, Fiegl H, Goebel G, Kopp F, et al. DNA ploidy, nuclear size, proliferation index and DNA hypomethylation in ovarian cancer. Gynecol Oncol. 2011;121: 24-31. http://dx.doi.org/10.1016/j.ygyno.2010.12.332 PMid:21251700 PMCid:PMC3062717 DOI: https://doi.org/10.1016/j.ygyno.2010.12.332
Lassus H, Staff S, Leminen A, Isola J, Butzow R. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol. 2011; 120(1):11-7. http://dx.doi.org/10.1016/j.ygyno.2010.09.003 PMid:20937525 DOI: https://doi.org/10.1016/j.ygyno.2010.09.003
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
